persimmon

領航 GMP 環境的 AI 風險控管：給高階主管的合規與確效架構指南

Sat, 23 May 2026 19:39:02 GMT

掌握如何在符合台灣與國際 PIC/S GMP 規範下導入生成式 AI。深入解析歐盟 Annex 22、FDA 警告信及品質單位審查的關鍵受控架構

Navigating AI Risks in GMP: A Strategic Guide for C-Suite

Sat, 23 May 2026 19:36:05 GMT

Learn how to align generative AI with strict GMP standards. This strategic analysis covers EU Annex 22, FDA enforcement, and validatable architecture guidelines.

FDA 警告信解析：Respilon 廠規與 PIC/S GMP 合規恢復策略

Sat, 23 May 2026 09:39:36 GMT

深度剖析 FDA 對 Respilon Production S.R.O. 發出的警告信。為藥廠高層與品質主管提供關鍵的數據完整性、製程確效與合規恢復路徑。

FDA Warning Letter to Respilon: Strategic Compliance Recovery

Sat, 23 May 2026 09:37:32 GMT

A deep-dive analysis of the FDA Warning Letter to Respilon Production S.R.O. Learn the strategic path to CGMP compliance and regulatory recovery.

FDA 483 案例分析：無菌製劑確效失誤與污染風險

Thu, 21 May 2026 16:19:56 GMT

梁山工程顧問有限公司針對 Asteria Health 的 FDA Form 483 進行深度技術分析，聚焦製程確效、數據完整性與無菌控制盲點。

FDA 483 Case Study: Sterile Compounding Validation Failures

Thu, 21 May 2026 16:15:31 GMT

Persimmon Engineering analysis of FDA Form 483 observations at Asteria Health, focusing on process validation, data integrity, and critical contamination risks.

新世代電腦化系統確效：GAMP 5 第二版技術實務指南

Thu, 21 May 2026 15:16:57 GMT

深入探討新世代電腦化系統確效（CSV）如何利用 GAMP 5 第二版精神、批判性思考與自動化確效工具，協助生技製藥廠在數位轉型中維持受控狀態。

Next-Gen CSV: GAMP 5 2nd Edition Validation Strategies

Thu, 21 May 2026 15:14:08 GMT

Learn how next-generation Computerized System Validation (CSV) leverages GAMP 5 Second Edition, critical thinking, and automated lifecycle verification tools.

掌握優良文件作業規範 (GDP) 實務指南 | 梁山工程顧問

Wed, 06 May 2026 16:36:03 GMT

深入解析生技製藥產業中不可或缺的優良文件作業規範 (GDP) 逐步指南。在 GMP 嚴格環境下，精準掌握核心法規遵循策略、ALCOA+ 數據完整性原則、以及 FDA 21 CFR Part 11 電腦化系統確效 (CSV) 實務。從批次製造紀錄、製程偏差管理到電子簽章防護，全面建立零缺失的品質系統與追溯防線，保護企業免受法規懲處。

Mastering Good Documentation Practice (GDP) | Persimmon Engineering

Wed, 06 May 2026 16:34:06 GMT

Discover the ultimate step-by-step guide to Good Documentation Practice (GDP) in GMP environments. Learn ALCOA+ principles, data integrity, and CSV compliance.

ATMP 法規遵循：高階主管的精準醫療策略指南

Wed, 06 May 2026 14:06:54 GMT

深入探討 ATMP 法規遵循如何影響企業營運。專為高階主管打造的指南，解析法規風險、風險導向方法 (RBA) 以及確保生命週期的追溯性。

ATMP Compliance: A Strategic Guide for C-Suite Executives

Wed, 06 May 2026 14:04:51 GMT

Discover how ATMP compliance impacts your bottom line. A deep dive for executives on navigating regulatory risks, the RBA, and ensuring lifetime traceability.

FDA AI警告信稽核：Purolea QCU AI自動化與實體廠房缺失解析 |梁山工程顧問

Thu, 30 Apr 2026 07:46:31 GMT

專為法規稽核員與品保經理打造的FDA首封AI警告信(Purolea)深度解析指南。深入探討21 CFR法規遵循、QCU人員介入(Human-in-the-Loop)控制要求與實體GMP風險。立即了解如何避免因過度依賴自動化而導致的CSV與製程確效缺失，全面鞏固數位與實體合規防線。

FDA AI Warning Letter: Auditing Purolea QCU Automation Risks

Thu, 30 Apr 2026 07:42:31 GMT

A regulatory auditor's guide to the FDA's first AI warning letter (Purolea). Explore 21 CFR compliance, QCU human-in-the-loop controls, and physical GMP risks.

FDA 警告信 320-26-58：深度解析 AI 過度依賴 | 梁山工程顧問

Thu, 30 Apr 2026 06:11:06 GMT

梁山工程顧問(Persimmon Engineering)為高階主管提供的 FDA 警告信 320-26-58 深度解析。了解在 CGMP 設施中部署未經驗證的 AI 所帶來的嚴峻法規與財務風險。

FDA Warning 320-26-58: Deep Dive into AI Overreliance | Persimmon Engineering

Thu, 30 Apr 2026 06:08:54 GMT

An executive deep-dive analysis of FDA Warning Letter 320-26-58. Understand the critical regulatory and financial risks of deploying unverified AI in CGMP facilities.

FDA CP 7356.002A：無菌製劑製程查廠指南 | 梁山工程顧問

Wed, 29 Apr 2026 14:57:18 GMT

專為品保經理與廠長打造的 FDA CP 7356.002A 深度法規解析。掌握無菌製劑製程查廠重點，確保符合 CGMP 與無菌保證規範。

FDA CP 7356.002A: Sterile Drug Process Inspections Guide

Wed, 29 Apr 2026 14:55:14 GMT

A regulatory deep-dive into FDA Compliance Program 7356.002A for QA Managers & Facility Directors. Master sterile drug process inspections and CGMP compliance.

FDA 7346.832M 數據完整性與電腦化系統確效 (CSV) 指南 | 梁山工程顧問

Wed, 29 Apr 2026 12:27:31 GMT

掌握 FDA 7346.832M 查廠指南核心目標二：了解如何透過嚴謹的權限控管與稽核追蹤，鞏固生技廠的數據完整性與電腦化系統確效(CSV)。

FDA 7346.832M Data Integrity & CSV Guide for QA Managers

Wed, 29 Apr 2026 12:25:16 GMT

Master FDA Compliance Program 7346.832M Objective 2. Learn how to bulletproof your Computerized System Validation (CSV), access controls, and audit trails.

FDA CDER合規計畫 7346.832M：生物製品PLI與PAI查廠指南

Wed, 29 Apr 2026 08:28:33 GMT

深入解析FDA CDER 7346.832M合規計畫。掌握生物製品上市前(PLI)與核准前(PAI)查廠的關鍵重點，包含品質系統、確效工程、製程管制與數據完整性。

FDA CDER 7346.832M: Prelicense & Preapproval Biologics Inspections

Wed, 29 Apr 2026 08:26:09 GMT

A deep dive into FDA CDER Compliance Program 7346.832M. Learn how to prepare for PLI and PAI inspections, focusing on quality systems, validation, and data integrity.

查廠後之資源整併與品質文化建立：設施處長 FDA 483 缺失回覆指南 | 梁山工程顧問

Wed, 15 Apr 2026 15:57:59 GMT

設施處長必須以強大的治理能力與資源分配引領 FDA 483 回覆。了解如何在查廠後建立具韌性的品質文化與系統性 CAPA。

Aligning Resources & Quality Culture Post-FDA 483

Wed, 15 Apr 2026 15:55:27 GMT

Facility Directors must lead FDA 483 responses with strong governance and resource allocation. Learn how to build a resilient quality culture post-inspection.

Strategic Transformation in Medical Software: From GAMP 5 Modernization to SMART on FHIR Excellence

Tue, 14 Apr 2026 14:46:08 GMT

Persimmon Engineering explores the shift in digital health infrastructure by integrating GAMP 5, TFDA SaMD regulations, and FHIR standards for 100% operational

醫療軟體導入的戰略轉型：從 GAMP 5 現代化準則到 SMART on FHIR 的卓越合規路徑

Tue, 14 Apr 2026 14:43:41 GMT

梁山工程顧問探討如何整合 GAMP 5 現代化準則、TFDA SaMD 法規與 HL7 FHIR 標準，透過 25 年工程傳承，建構百分之百營運就緒的數位醫療基礎設施。

FDA Warning Letter Analysis: Yangzhou H&R Plastic & CGMP Failures

Tue, 14 Apr 2026 09:45:50 GMT

Deep dive into the FDA Warning Letter issued to Yangzhou H&R Plastic. Learn how QA failures, missing process validation, and weak QUs lead to import alerts.

FDA警告信分析：揚州H&R塑膠日化CGMP重大缺失

Tue, 14 Apr 2026 09:45:47 GMT

深入探討揚州H&R塑膠日化所收到的FDA警告信。了解檢驗超標、缺乏製程確效與薄弱的品質管理系統如何導致進口警報，以及如何透過專業顧問進行改善。

The Strategic Blueprint for High-Performance Pharma & Biotech Facilities

Sun, 12 Apr 2026 20:41:14 GMT

Discover how specialized GMP engineering and owner representative services ensure strict PIC/S and FDA compliance, reducing risks and accelerating time-to-market.

高效能生技與製藥廠房的戰略藍圖

Sun, 12 Apr 2026 20:41:12 GMT

深入探討專業的 GMP 工程與業主代表服務如何確保生技製藥廠房設計嚴格符合 PIC/S GMP 與 FDA 標準，有效降低法規合規風險，並加速關鍵產品的上市時間。

製藥用水與蒸汽系統之紅鏽現象：成因探討與控制策略

Sat, 11 Apr 2026 13:09:10 GMT

深入探討不鏽鋼氧化機理與紅鏽現象等級分類，並制定具體之生命週期管理策略，以確保藥廠設施符合 GMP 合規性要求。

Primary Keywords: Rouging, Pharmaceutical Water Systems, Pure Steam Systems, Derouging, Passivation.

Targeted Phrases : Causes of rouging in stainless steel, how to control rouging in WFI systems, thermal sanitisation effects on rouging, Class I II III rouging classification.

Hashtags : #PharmaEngineering #WaterSystems #Rouging #GMPCompliance #SystemValidation #PersimmonEngineering.

GDP 專任人員 (Responsible Person) 之資質要求

Sat, 11 Apr 2026 13:01:07 GMT

掌握藥品優良運銷規範 (GDP) 專任人員之法規架構、必備資質及組織職掌。

Primary Keywords GDP Responsible Person, Good Distribution Practice, GDP Requirements, Quality Management, Pharma Compliance

Targeted Phrases Duties of a GDP responsible person, EU GDP Guidelines 2013/C 343/01, pharmaceutical wholesale distribution compliance, GDP training and QMS implementation, role of RP in medicinal product logistics

Hashtags #GDP #PharmaCompliance #QualityManagement #RegulatoryAffairs #PersimmonEngineering

藥品優良運銷規範（GDP）要項

Sat, 11 Apr 2026 12:52:40 GMT

藥品供應鏈完整性、法規遵循及健全品質管理體系之綜合指南。

Primary Keywords: Good Distribution Practice, GDP compliance, pharmaceutical logistics, supply chain integrity

Targeted Phrases: EU GDP Guidelines for human medicinal products, pharmaceutical quality management system requirements, cold chain management for medicinal products, handling pharmaceutical product recalls

Hashtags: #PharmaLogistics #GDPCompliance #SupplyChainSafety #DrugSafety #QualityManagement

生物製品之 GMP 合規性

Sat, 11 Apr 2026 12:43:31 GMT

遵循歐洲及國際生物技術產品之 GMP 規範，重點針對製程管制、病毒安全性及固有變異性進行評析。

Primary Keywords (Short-Tail) GMP Compliance, Biologics, Pharma Regulations, Quality Control, EU GMP.

Targeted Phrases (Long-Tail) GMP requirements for biotechnological products, EU GMP Annex 2 compliance, ICH Q5A virus safety standards, biological process validation, critical process parameters in pharma.

Hashtags #Biologics #GMPCompliance #PharmaTech #RegulatoryAffairs #QualityControl

EMA GMP 規範修訂進度表 (2026-2028)

Sat, 11 Apr 2026 12:34:47 GMT

積極籌備歐洲藥品管理局（EMA）之新年度三年工作計畫，涵蓋《附錄 15》、《附錄 22》及 GMP 重點章節之修訂與更新。

Primary Keywords: EMA GMP Guidelines, GMDP IWG, Annex 15 Validation, Annex 22 AI

Targeted Phrases: EMA 3-year work plan for GMP inspectors, revision of GMP requirements 2026, Annex 22 Artificial Intelligence guidelines

Hashtags: #EMAGMP #RegulatoryCompliance #PharmaValidation #Annex15 #Annex22

以患者為中心的先進治療(ATMP)法規產品規格

Sat, 11 Apr 2026 12:24:45 GMT

憑藉專家洞察，掌握自體細胞與基因治療轉向「以患者為中心」品質屬性的法規趨勢。

Primary Keywords (Short-Tail) ATMP, Cell Therapy, Gene Therapy, Regulatory Compliance, ICH Guidelines, Patient-Centric.

Targeted Phrases (Long-Tail) Patient-centric specifications for ATMPs, Autologous cell therapy regulatory guidelines, Overcoming out-of-specification in cell therapies, ECA ATMP Group position paper summary, Pharmaceutical validation for advanced therapies.

Hashtags #ATMP #CellTherapy #RegulatoryCompliance #PatientCentricity #PharmaTech #PersimmonEngineering #Validation

FDA 警示函：無菌製程缺失

Sat, 11 Apr 2026 12:15:34 GMT

針對 Simtra BioPharma 現行藥品優良製造規範 (cGMP) 違規事項之深度分析：重點指出設備死角 (Dead Legs)、矯正與預防措施 (CAPA) 失效及系統性污染所引發的風險。

Primary Keywords FDA Warning Letter, Aseptic Manufacturing, CGMP Compliance, CAPA, Simtra BioPharma

Targeted Phrases resolving FDA Form 483 observations, correcting dead legs in pharmaceutical piping, preventing sterile manufacturing contamination, implementing effective CAPA in pharma, unannounced FDA inspections in Europe

Hashtags #PharmaCompliance #FDAWarningLetter #AsepticManufacturing #CGMP #QualityAssurance #PersimmonEngineering #CAPA

FDA 警示函：矯正預防措施 (CAPA) 與根本原因分析失效

Sat, 11 Apr 2026 11:55:38 GMT

探究 OraLabs Inc. 近期 FDA 警示函中的關鍵 GMP 違規事項。深入瞭解為何嚴謹的根本原因分析（Root Cause Analysis）對於落實合規至關重要。

Primary Keywords FDA Warning Letter, CAPA Process, Root Cause Analysis, GMP Violation, 21 CFR 211.192.

Targeted Phrases inadequate root cause analysis in pharma, FDA inspection CAPA actions, microbiological deviation investigations, CFR 211.192 compliance, pharmaceutical lot release risks.

Hashtags #FDACompliance #GMP #CAPA #RootCauseAnalysis #PharmaManufacturing #RegulatoryAffairs #PersimmonEngineering

FDA 警示函：設備設計對生物薄膜（Biofilm）形成之影響與風險評估

Sat, 11 Apr 2026 11:24:00 GMT

探討製藥用水系統因忽視性能驗證（PQ）失效及系統性死角（Dead Legs），最終引發 FDA 警告信之始末。

Primary Keywords (Short-Tail): FDA Warning Letter, Hygienic Design, Water Systems, Biofilm, Equipment Qualification.

Targeted Phrases (Long-Tail): Dead legs in pharmaceutical water systems, Performance Qualification (PQ) failures, FDA cGMP equipment design compliance, Resolving stagnant piping locations, Waterborne microbiological contamination.

Hashtags: #PharmaCompliance #FDAWarningLetter #HygienicDesign #Validation #PersimmonEngineering.

FDA 警示函：嚴重的數據完整性缺失

Sat, 11 Apr 2026 11:09:13 GMT

某印度實驗室因系統性數據銷毀、紀錄追溯（倒填日期）及阻礙檢查，面臨 FDA 處分。本文探討此類行為對現行藥品優良製造規範（CGMP）合規性之影響

Primary Keywords: FDA Warning Letter, Data Integrity, CGMP Compliance, Pharma Quality Assurance, OOS Results, Data Governance, Lab Validation

Targeted Phrases (Long-Tail): FDA data integrity violations, Contract testing laboratory warning letter, CGMP documentation practices, Out-of-specification (OOS) investigations, Falsified analytical records FDA, Pharmaceutical CAPA tracking, Persimmon Engineering compliance audit

Hashtags: #FDACompliance #DataIntegrity #CGMP #PharmaTech #QualityAssurance #RegulatoryAffairs #PersimmonEngineering #DataGovernance

GDP Responsible Person Requirements

Fri, 10 Apr 2026 08:31:36 GMT

Master the regulatory framework, essential qualifications, and organizational duties for a Good Distribution Practice (GDP) Responsible Person.